Cogent Biosciences, Inc.

COGT - CIK 0001622229

Market cap$5.36 B

Rank#1334

SEC filings595

Cogent Biosciences, Inc. trades as COGT and has a market capitalization of $5.36 B, making it the #1334 largest US-listed company by market value. This page tracks Cogent Biosciences, Inc. through 595 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$7.87MFY 2020

Net income (latest FY)-$328.94MFY 2025

Operating cash flow (latest FY)-$264.44MFY 2025

Total assets (latest FY)$937.61MFY 2025

Financial performance

Net profit margin compressed from -304.9% to -950.4% over the same period - every figure below comes from the company's audited annual filings.

COGT annual revenueView details

COGT annual net incomeView details

Key statistics

Market cap: $5.36 B
Share price (derived)market cap / shares outstanding: $31.38
EPS (diluted)FY 2025: $-2.16
Shares outstandingas of 2026-05-01: 0.17B
Total equityas of 2026-03-31: $607.69M
Return on equity: -54.1%
Long-term debtas of 2026-03-31: $223.17M
Cash & equivalentsas of 2026-03-31: $241.21M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-21
SCHEDULE 13G/A	-	2026-05-14
Quarterly report	10-Q	2026-05-05
Major company event	8-K	2026-05-05
Annual report to shareholders	ARS	2026-04-23
Proxy materials	DEFA14A	2026-04-23
Proxy statement	DEF 14A	2026-04-23
Insider trade	4	2026-04-03

Browse the full filing history (595 filings)

Recent press releases

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference2026-05-27
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference – Cogent Biosciences, Inc.
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress2026-05-12
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress – Cogent Biosciences, Inc.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results2026-05-05
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results – Cogent Biosciences, Inc.
Cogent Biosciences Announces Oral Presentation Positive Phase 32026-04-21
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting – Cogent Biosciences, Inc.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 20262026-04-17
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 – Cogent Biosciences, Inc.

Similar companies

The largest companies sharing Cogent Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.070 T COGT vs LLY

JNJJohnson & Johnson$574.10 B COGT vs JNJ

ABBVAbbVie Inc.$397.44 B COGT vs ABBV

MRKMerck & Co., Inc.$294.13 B COGT vs MRK

AZNAstraZeneca PLC$286.27 B COGT vs AZN

Frequently asked questions

What is Cogent Biosciences, Inc.'s market cap?

Cogent Biosciences, Inc. (COGT) has a market capitalization of $5.36 B as of 2026-06-11, ranking #1334 among US-listed companies.

Is Cogent Biosciences, Inc. profitable?

In its latest fiscal year Cogent Biosciences, Inc. reported a net loss of $328.94M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.